Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients

Antiplatelet agents are routinely used to treat patients with chronic atherosclerotic coronary artery disease. Treatment with the addition of a low dose of rivaroxaban as dual-pathway inhibition (DPI) decreases ischaemic events at the expense of increased bleeding. At present, the balance between th...

Descripción completa

Detalles Bibliográficos
Autores principales: Komiyama, Maki, Dan, Gheorghe-Andrei, Hasegawa, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2023
Materias:
Pharmacotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316355/
https://www.ncbi.nlm.nih.gov/pubmed/37405346
http://dx.doi.org/10.15420/ecr.2022.66

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316355/
https://www.ncbi.nlm.nih.gov/pubmed/37405346
http://dx.doi.org/10.15420/ecr.2022.66

Ejemplares similares